{"schema":"sb.truth.v1","subject":"regulatory-approval-bristol-myers-squibb-fda","title":"The Regulatory approval: Bristol Myers Squibb & FDA record","tier":"standard","tierNote":"Standard-tier record, generated from the maintained event registry: reporting, our coverage metric, market expectation, and state history. No primary-source layer yet — first-party issuer verification is what upgrades a record to full tier, the discipline the hormuz record demonstrates.","subjectBinding":{"entity":"fda","bound":true,"basis":"named-in-subject","statement":"Lead subject \"fda\" — named in this record's own subject line (\"Regulatory approval: Bristol Myers Squibb & FDA\"). It was preferred over bristol myers squibb because it carries this record's own action class (regulatory-approval) — the event this record is about, rather than a place or party named alongside it. The reporting, record, market and state-history layers below are that subject's own; none is borrowed from a neighbouring entity.","candidatesConsidered":["bristol myers squibb","fda"],"alsoDefensible":["bristol myers squibb"],"rejected":[],"actionClass":"regulatory-approval"},"publishState":"published","publishStateNote":null,"asOf":"2026-08-28","generatedAt":"2026-08-28T19:04:33.478410+00:00","tracked":true,"access":"Free — no key, no charge. Serves at GET /api/truth/regulatory-approval-bristol-myers-squibb-fda and answers the get_truth_object MCP tool. (No exhibit page for standard-tier records yet — the API and MCP responses ARE the record.)","attribution":"Cite 'Signal Bureau' with https://signalbureau.ai/api/truth/regulatory-approval-bristol-myers-squibb-fda so readers can verify.","layers":{"primarySources":{"label":"Observed operational state","status":"absent","basis":"not present on a standard-tier record — no first-party issuer has been routed for this subject yet; nothing here is previewed to look finished","sources":[]},"reporting":{"label":"Observed reporting","basis":"attributed sources — outside coverage in our tracked set; verify at the source. Prediction-market question pages are excluded: a venue question is not journalism, whoever hosts it. Filtered for EVENT relevance, not just subject: a row is served only if it names \"fda\" AND carries a term from this record's own subject line, or two terms from its market-question set. The subject's name alone is the key its corpus was sampled on, so it proves nothing about this event — each served row names the terms it matched in eventTerms.","status":"observed","note":"Event-relevance filtered: 5 attributable rows sampled for \"fda\", 2 served, 3 withheld as not shown to be about \"Regulatory approval: Bristol Myers Squibb & FDA\". The served count is reduced on purpose and reported, never quietly smaller.","sampledForSubject":5,"served":2,"withheldNotEventRelevant":3,"relevanceTerms":{"subjectLine":["regulatory","approval","bristol","myers","squibb"],"questionSet":[]},"items":[{"title":"FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer","url":"https://ascopost.com/news/august-2026/fda-approves-zanidatamab-combination-regimens-for-her2-gastric-gej-or-esophageal-cancer/","eventTerms":["approval"],"relevance":"subject-line-term","tier":"outlet","kind":"reporting — attributed; verify at the source"},{"title":"FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer","url":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer","eventTerms":["approval"],"relevance":"subject-line-term","tier":"outlet","kind":"reporting — attributed; verify at the source"}]},"record":{"label":"The record itself","basis":"our own count of documents we ingested and can name — not a claim about the world, and market questions are excluded because a question is not reporting","documents":709,"outlets":68,"activeDays":105,"firstSeen":"2026-04-06","firstSeenStatus":"observed","firstSeenNote":null,"lastSeen":"2026-08-22","lastSeenStatus":"observed","lastSeenNote":null,"homeDomains":["pharma-regulatory"],"asserts":{"regulatory-approval":388,"election":6,"acquisition":4,"legal-ruling":4,"meeting-visit":4,"military-action":4},"assertionCoverage":0.601,"movesWith":[{"name":"drug administration","together":233,"sharedDomains":["pharma-regulatory"]},{"name":"u.s. food","together":92,"sharedDomains":["pharma-regulatory"]},{"name":"cder","together":39,"sharedDomains":["pharma-regulatory"]},{"name":"drug evaluation","together":25,"sharedDomains":["pharma-regulatory"]},{"name":"safety information","together":25,"sharedDomains":["pharma-regulatory"]},{"name":"ai","together":49},{"name":"united states","together":34},{"name":"us food","together":32}],"movesWithLabels":["drug administration","u.s. food","cder","drug evaluation","safety information","ai","united states","us food"],"provenance":"curated"},"coverageMetric":{"label":"Coverage state","basis":"our own measurement — our attention, not the event's state","direction":"rising","baselineRelativePct":59,"reading":"Our coverage of Regulatory approval: Bristol Myers Squibb & FDA is 59% above its 3-week baseline. This measures our attention — how much our tracked set is writing about it — not the event itself.","trackedDays":108,"eventMentions":14,"periods":[{"period":"2026-08","mentions":14}]},"market":{"label":"Market expectation","basis":"attributed — markets price collective belief about defined outcomes; belief, not fact, and never proof that an event occurred","rowsStatus":"none-captured","rowsNote":"Measured zero: no priced capture rides \"fda\" in this build.","current":[],"arc":[],"eventArc":{"name":"Regulatory approval: Bristol Myers Squibb & FDA","slug":"regulatory-approval-bristol-myers-squibb-fda","questionCount":0,"questions":[],"mentions":14,"firstSeen":"2026-08-14","firstSeenStatus":"observed","lastSeen":"2026-08-14","lastSeenStatus":"observed","stampNote":null}},"judgment":{"label":"Our reading","basis":"derived judgment — our reading over the layers above; ours, and labeled ours","asOf":"2026-08-28","text":"A standard-tier record keeps its layers apart and does not collapse them. Lead subject \"fda\" — named in this record's own subject line (\"Regulatory approval: Bristol Myers Squibb & FDA\"). It was preferred over bristol myers squibb because it carries this record's own action class (regulatory-approval) — the event this record is about, rather than a place or party named alongside it. The reporting, record, market and state-history layers below are that subject's own; none is borrowed from a neighbouring entity. Our coverage metric measures our attention; the reporting is attributed, not verified against first-party issuers; the market layer prices belief, not fact. Reading any single layer as \"the answer\" is how a machine gets this wrong — and this record's honest limit is stated in its tier: no primary-source layer exists here yet."},"consensus":{"label":"Reporting consensus","basis":"retroactive claims ledger — kernel facts scored by independent-chain agreement","pending":true,"note":"No claims ledger has been computed for this subject yet — consensus scoring is full-tier machinery."},"stateHistory":{"label":"State history","basis":"recorded transitions — never edited after the fact","status":"recorded","note":null,"transitions":[{"field":"coverage state","from":"steady","to":"rising","at":"2026-08-26T15:13:20.917747+00:00","heldSince":"2026-08-23T15:05:52.843966+00:00"}]}}}